Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination analgesic therapy consists of the central analgesic acetaminophen (paracetamol) and the nonsteroidal anti-inflammatory drug (NSAID) ketorolac tromethamine. It is being investigated by the Universidade Estadual de Ponta Grossa for the prevention of tooth sensitivity associated with in-office dental bleaching procedures using 35% hydrogen peroxide. Ketorolac tromethamine acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins that mediate inflammation and pain, while acetaminophen provides complementary analgesic effects through central pathways. The treatment protocol involves oral administration starting one hour before the dental procedure and continuing every 8 hours for 48 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + ketorolac tromethamine.